Rapamycin increases breast tumor burden in young wheel-running mice
Open Access
- 1 January 2019
- journal article
- editorial
- Published by Taylor & Francis in Pathobiology of Aging & Age-related Diseases
- Vol. 9 (1) , 1647746
Abstract
Rapamycin is an immunosuppressive and anti-cancer drug recently shown to enhance healthy aging in animal models. Regular physical exercise is associated with healthy aging and reduced risk of age-related diseases, such as cancer. In order to test the combined effect of these approaches, mice with 4T1 breast cancer were fed rapamycin at 14 ppm and allowed access to voluntary running wheels. After 17 days of treatment, mice fed the rapamycin diet that ran showed a significant increase in tumor burden compared with mice that did not run (P = 0.017). Not only does this have implications for young breast cancer patients, but suggests that combining rapamycin and exercise as an anti-aging strategy at a young age might be contraindicated.Keywords
This publication has 7 references indexed in Scilit:
- Exercise enhances wound healing and prevents cancer progression during aging by targeting macrophage polarityMechanisms of Ageing and Development, 2014
- Exercise Training in Transgenic Mice Is Associated with Attenuation of Early Breast Cancer Growth in a Dose-Dependent MannerPLOS ONE, 2013
- Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female miceCell Cycle, 2011
- Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous MiceThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2010
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Rapamycin in transplantation: A review of the evidenceKidney International, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000